Levetiracetam (Epilepsy)

Neonatal disorders (as a whole)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S15842
R65218		 Bromley (Levetiracetam) (Controls exposed to LTG), 2023 Neonatal complications during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick excluded Adjustment: No 0.90 [0.43;1.90] C
excluded (control group) 		14/70   23/106 37 70
ref
S15843
R65231		 Bromley (Levetiracetam) (Controls unexposed, sick), 2023 Neonatal complications during pregnancy (anytime or not specified) prospective cohort unexposed, sick Adjustment: No 1.08 [0.48;2.44] C 14/70   15/80 29 70
ref
S7807
R23113		 Coste (Levetiracetam) (Controls unexposed, NOS), 2020 Neonatal condition during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 1.06 [0.84;1.34] C 85/621   222,201/1,710,441 222,286 621
ref
Total 2 studies 1.06 [0.85;1.33] 222,315 691
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Bromley (Levetiracetam) (Controls unexposed, sick), 2023Bromley, 2023 1 1.08[0.48; 2.44]29707%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: moderateROB mesure: moderateROB reporting: low Coste (Levetiracetam) (Controls unexposed, NOS), 2020Coste, 2020 2 1.06[0.84; 1.34]222,28662193%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 0% 1.06[0.85; 1.33]222,3156910.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Levetiracetam) (Controls unexposed, sick; 2: Levetiracetam) (Controls unexposed, NOS;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.06[0.85; 1.33]222,3156910%NABromley (Levetiracetam) (Controls unexposed, sick), 2023 Coste (Levetiracetam) (Controls unexposed, NOS), 2020 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.06[0.84; 1.34]222,286621 -NACoste (Levetiracetam) (Controls unexposed, NOS), 2020 1 unexposed, sickunexposed, sick 1.08[0.48; 2.44]2970 -NABromley (Levetiracetam) (Controls unexposed, sick), 2023 1 Tags Adjustment   - No  - No 1.06[0.85; 1.33]222,3156910%NABromley (Levetiracetam) (Controls unexposed, sick), 2023 Coste (Levetiracetam) (Controls unexposed, NOS), 2020 2 All studiesAll studies 1.06[0.85; 1.33]222,3156910%NABromley (Levetiracetam) (Controls unexposed, sick), 2023 Coste (Levetiracetam) (Controls unexposed, NOS), 2020 20.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 15842

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.06[0.84; 1.34]222,286621 -NACoste (Levetiracetam) (Controls unexposed, NOS), 2020 1 unexposed, sick controlsunexposed, sick controls 1.08[0.48; 2.44]2970 -NABromley (Levetiracetam) (Controls unexposed, sick), 2023 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.90[0.43; 1.90]3770 -NABromley (Levetiracetam) (Controls exposed to LTG), 2023 10.510.01.0